Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT05314439 | A Study to Assess the Safety, Tolerability, and Efficacy of Monthly Subcutaneous Administration of ION904 in Participants With Uncontrolled Hypertension | PHASE2 | COMPLETED | 48 | — | — | Apr 29, 2022 | Feb 15, 2023 | Dec 22, 2023 | 8 | United States |
| Arm | Type | Description |
|---|---|---|
| ION904 | EXPERIMENTAL | Up to 4 monthly doses of ION904 will be administered by subcutaneous (SC) injection. |
| Placebo | PLACEBO_COMPARATOR | Up to 4 monthly doses of placebo will be administered by SC injection. |
| Name | Type | Description |
|---|---|---|
| ION904 | DRUG | ION904 will be administered by SC injection. |
| Placebo | DRUG | Placebo will be administered by SC injection. |
General Inclusion Criteria: 1. Males must be surgically sterile or, abstinent or, if engaged in sexual relations with a woman of child-bearing potential (WOCBP), she uses a highly effective contraceptive method. Aged 18 - 75 inclusive and weighing ≥ 50 kilograms (kg) at the time of informed consent...